Karın Şişkinliği
Özet
Karın şişkinliği, toplumda yaygın görülen ve yaşam kalitesini ciddi oranda düşüren fonksiyonel bir gastrointestinal sistem bozukluğudur. Roma IV kriterlerine göre tanımlanan bu durum, yapısal veya biyokimyasal bir bozukluk olmaksızın tekrarlayan şişkinlik ve distansiyon hissi ile karakterizedir. Kadınlarda erkeklere oranla 2 ila 4 kat daha sık rastlanan bu semptomun etyopatogenezi tam olarak bilinmemekle birlikte; barsak mikrobiyotasındaki dengesizlikler, visseral hipersensivite, gıda intoleransları, gaz klirensinde bozulma ve ince barsakta aşırı bakteri çoğalması (SIBO) gibi multifaktöriyel mekanizmalar suçlanmaktadır. Tanı aşamasında anemi, kilo kaybı ve ailede kanser öyküsü gibi "alarm semptomlarının" varlığı titizlikle araştırılmalı; organik hastalıkları dışlamak için radyolojik ve endoskopik tetkikler kullanılmalıdır. Tedavi süreci oldukça kompleks olup yaşam tarzı değişiklikleri, beslenme modifikasyonları (düşük FODMAP veya glutensiz diyet), probiyotik kullanımı ve simetikon veya rifaksimin gibi medikal ajanları kapsamaktadır. Ayrıca, fiziksel aktivite ve karın duvarı anormalliklerini gidermeye yönelik biyofeedback tedavileri de semptomların hafifletilmesinde etkili olabilmektedir. Sonuç olarak, bireysel mekanizmaların çeşitliliği nedeniyle tedavi planı her hasta için özel olarak yapılandırılmalıdır.
Abdominal bloating is a common functional gastrointestinal disorder that significantly reduces the quality of life and is characterized by recurrent feelings of fullness and measurable distension without underlying structural or biochemical abnormalities according to Rome IV criteria. This symptom, which is observed 2 to 4 times more frequently in women than in men, has a multifactorial etiopathogenesis involving mechanisms such as imbalances in gut microbiota, visceral hypersensitivity, food intolerances, impaired gas clearance, and small intestinal bacterial overgrowth (SIBO). During the diagnostic phase, "alarm symptoms" such as anemia, weight loss, and a family history of cancer must be carefully investigated, and radiological or endoscopic examinations should be utilized to exclude organic diseases. The treatment process is complex, encompassing lifestyle changes, dietary modifications (such as low FODMAP or gluten-free diets), the use of probiotics, and medical agents like simethicone or rifaximin. Additionally, physical activity and biofeedback therapies aimed at correcting abdominal wall abnormalities can be effective in alleviating symptoms. Consequently, due to the diversity of individual mechanisms, the treatment plan must be specifically structured for each patient.
Referanslar
Sperber AD, Bangdiwala SI, Drossman DA , et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology 2020;160:99–114.
Abdullah N, Kueh YC, Kuan G, et al. Development and validation of the Health Promoting Behaviour for Bloating (HPB-Bloat) scale. PeerJ 2021; 11444.
Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-1491.
Lee HJ, Choi JK, Ryu HS, et al. Therapeutic modulation of gut microbiota in functional bowel disorders. J Neurogastroenterol Motil. 2017; 23: 9- 19.
Mearin F, Lacy, BE, Chang L, et al. Bowel disorders. Gastroenterology 2016;150:1393–1407.
Mari A, Backer FA, Mahamid M, et al. Bloating and abdominal distension: Clinical approach and management. Adv. Ther. 2019,;36:1075–1084.
Hosseini-Asl MK, Taherifard E, Mousavi MR. The effect of a short-term physical activity after meal on gastrointestinal symptoms in individuals with functional abdominal bloating: a randomized clinical trial. Gastroenterol Hepatol Bed Bench. 2021;14: 59–66.
Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 1998;42:690-695.
Sandler RS, Stewart WF, Liberman JN, et al. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. Dig Dis Sci 2000;45:1166-1171.
Burta O, Iacobescu C, Mateescu RB, et al. Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: A multicentre, randomised, double-blind, parallel group, clinical study. Transl. Gastroenterol. Hepatol. 2018;3:72.
Erdrich S, Hawrelak JA, Myers SP, et al. A systematic review of the association between fibromyalgia and functional gastrointestinal disorders. Therap Adv Gastroenterol 2020;13:1–17.
King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998;352:1187-1189.
Lewis M. Ambulatory abdominal inductance plethysmography: towards objective assessment of abdominal distension in irritable bowel syndrome. Gut. 2001;48:216–220.
Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and rome IV. Gastroenterology 2016;150:1262-1279.
Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol. 2007;3:112–122.
Foley A.. Burgell R, Barrett JS, et al. Management strategies for abdominal bloating and distension. Gastroenterol Hepatol. 2014;10:561–571.
Keeling WF, Martin BJ. Gastrointestinal transit during mild exercise. J Appl Physiol 1987;63:978-981.
Rej A, Aziz I, Tornblom H, et al. The role of diet in irritable bowel syndrome: Implications for dietary advice. J. Intern. Med. 2019; 286:490–502.
Kua CH, Ng ST, Lhode R, et al. Irritable bowel syndrome and other gastrointestinal disorders: evaluating self-medication in an Asian community setting. International Journal of Clinical Pharmacy 2012;34:561–568.
Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, et al. Effect of antispasmodic agents, alone or in combination, in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex 2012;77:82-90.
Maconi G. Diagnosis of symptomatic uncomplicated diverticular disease and the role of Rifaximin in management. Acta Biomed. 2017; 88:25–32.
Ringel-Kulka T, Palsson O, Maier D, et al. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders. J Clin Gastroenterol.2011;45(6):518–525.
